|
|
 |
|
Viewing report
|
|
|
|
Dyslipidemia - Statins Dominate Treatment Pathway - For Now
Datamonitor, Oct 2005, Pages: 204
Introduction
We estimate that there are 267m people in the seven major markets with total cholesterol >200mg/dL which is set to rise to 287m in 2015. Despite this vast patient potential, low diagnosis rates limit the market size, and with the launch of generic statins, and the maturing of the market, it is increasingly important for companies to target the under-treated dyslipidemia sub-populations.
Scope
- 180 physician interviews carried out across the seven major pharmaceutical markets, plus the views of key industry opinion leaders
- Examination of dyslipidemia patient potential, detailing the current and future prevalence of high total cholesterol
- Detailed treatment trees to show dyslipidemia patient flows at country levels (US, Japan, France, Germany, Italy, Spain and the UK)
- Expected future prescribing rates for combination therapy and new agents, such as Vytorin (ezetimibe + simvastatin) and atorvastatin and torcetrapib
Highlights
Dyslipidemia patients are often plagued with risk factors and co-morbidities that increase their relative risk considerably. Datamonitor research found that a high percentage of patients with dyslipidemia also suffer from obesity, hypertension and type 2 diabetes, representing a potentially lucrative target.
The more aggressive approach to LDL lowering, and lower treatment thresholds recommended in updated guidelines means a greater patient population. However, increasing awareness in physicians and in the general population is essential to increase diagnosis and thus treatment rates.
Physicians predict that combination therapy will play an increasingly important role over the next three years. Given the highly competitive nature of the antidyslipidemic market, companies that can position novel products as effective treatments for use in combination therapy are likely to be the most successful.
Reasons to Purchase
- Gain independent insight into the management of dyslipidemia and understand what factors influence physicians prescribing practices
- Assess the future direction of dyslipidemia therapy, and the remaining unmet needs in order to successfully manage your developmental products
- Identify lucrative new target populations in order to create new opportunities in this market
Customers who bought this item also bought
Stakeholder Insight: Dyslipidemia - Titration versus Combination Therapy
Dyslipidemia: Opportunities in Cardiovascular Risk Reduction
Pipeline Insight: Dyslipidemia - Pipeline Agents Unlikely To Rejuvenate The Market
Statin Adjunct Therapy - Zetia, Revenue Protection for Zocor?
Pipeline Insight: Dyslipidemia - Shift from statins to add-ons
Dyslipidemia: The Expanding Market for Statins and other Lipid Management Products
Stakeholder Insight: HIV Therapy Dynamics
The Dyslipidemia Market: Can Growth Be Sustained as Statin Patents Expire?
Prescribing for Elderly Patients
Drugs of Tomorrow 2001: Dyslipidemia - The Advent of Third Generation and Combination Statins
Stakeholder Insight: Asthma - Combination Therapy Appropriate for Everyone?
Cell Therapy - Technologies, Markets and Companies
|
|
|
|
